Immuneering Corp Appoints Andrew Gengos As CFO
(RTTNews) - Immuneering Corporation (IMRX), a late-stage clinical oncology company, Monday announced that it has appointed Andrew Gengos as Chief Financial Officer, effective July 16.
Most recently, Gengos served as the Chief Financial Officer at Terns Pharmaceuticals, which Merck & Co., Inc. acquired for $6.7 billion.
Prior to Terns Pharmaceuticals, he was the CFO and Chief Business Officer of Athira Pharma, Inc. now LeonaBio, Inc.
In pre-market activity, IMRX shares were trading at $4.24, up 1.41% on the Nasdaq.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.